Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

Clinical trial NCT02414269 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02414269
Sponsor: Memorial Sloan Kettering Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Malignant Pleural Disease Mesothelioma Metastases Lung Cancer Breast Cancer

Start date: 2015-05-01
Primary completion: 2027-04-30
Enrollment: 113

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.